Underexpression of miR-34a in Hepatocellular Carcinoma and Its Contribution towards Enhancement of Proliferating Inhibitory Effects of Agents Targeting c-MET

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Dang, Yiwu ^a   Luo, Dianzhong ^a   Rong, Minhua ^b   Chen, Gang ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 34A; MITOGEN ACTIVATED PROTEIN KINASE 3; SCATTER FACTOR RECEPTOR; STAT5A PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER STAGING; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR EMBOLISM; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DNA PRIMERS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84876042176     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061054     Document Type: Article

References (31)

1. Hummel R, Hussey DJ, Haier J, (2010) MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 46: 298-311.
2. Meguro M, Mizuguchi T, Kawamoto M, Hirata K, (2011) The molecular pathogenesis and clinical implications of hepatocellular carcinoma. Int J Hepatol 2011: 818672.
3. Hu Z, Zhao W, (2012) Novel insights into the molecular mechanisms of alpha-fetoprotein expression and malignant phenotypes of hepatocellular carcinoma. Cell Mol Immunol 9: 7-8.
4. Hu L, Chen G, Yu H, Qiu X, (2010) Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int 4: 423-432.
5. Chen G, Luo D, (2008) Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India 21: 275-278.
6. Chen G, Dang YW, Luo DZ, Feng ZB, Tang XL, (2008) Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study. Oncol Res 17: 183-189.
7. Yang M, Chen G, Dang Y, Luo D, (2010) Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Ups J Med Sci 115: 232-237.
8. Chen G, Luo DZ, Liu L, Feng ZB, Guo F, et al. (2006) Hepatic local micro-environmental immune status in hepatocellular carcinoma and cirrhotic tissues. West Indian Med J 55: 403-408.
9. Karabork A, Kaygusuz G, Ekinci C, (2010) The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma. Pathol Res Pract 206: 572-577.
10. Chen G, Rong M, Luo D, (2010) TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell. Pathol Res Pract 206: 631-641.
11. Augello C, Vaira V, Caruso L, Destro A, Maggioni M, et al. (2012) MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int 32: 772-782.
12. Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, et al. (2011) MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One 6: e16435.
13. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, et al. (2010) miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107: 264-269.
14. Li N, Fu H, Tie Y, Hu Z, Kong W, et al. (2009) miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 275: 44-53.
15. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134.
16. Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, et al. (2013) A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer 108: 21-24.
17. Koivusalo R, Krausz E, Helenius H, Hietanen S, (2005) Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol Pharmacol 68: 372-382.
18. Tryndyak VP, Ross SA, Beland FA, Pogribny IP, (2009) Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet. Mol Carcinog 48: 479-487.
19. Sukata T, Sumida K, Kushida M, Ogata K, Miyata K, et al. (2011) Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett 200: 46-52.
20. Cheng J, Zhou L, Xie QF, Xie HY, Wei XY, et al. (2010) The impact of miR-34a on protein output in hepatocellular carcinoma HepG2 cells. Proteomics 10: 1557-1572.
21. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745-752.
22. Inagaki Y, Qi F, Gao J, Qu X, Hasegawa K, et al. (2011) Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends 5: 52-56.
23. Syed ZA, Yin W, Hughes K, Gill JN, Shi R, et al. (2011) HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer 11: 180.
24. Dai Y, Siemann DW, (2012) Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer 12: 198.
25. Tsou HK, Chen HT, Hung YH, Chang CH, Li TM, et al. (2013) HGF and c-Met interaction promotes migration in human chondrosarcoma cells. PLoS One 8: e53974.
26. Lin YM, Huang YL, Fong YC, Tsai CH, Chou MC, et al. (2012) Hepatocyte growth factor increases vascular endothelial growth factor-A production in human synovial fibroblasts through c-Met receptor pathway. PLoS One 7: e50924.
27. Chen G, Kronenberger P, Teugels E, De Greve J, (2011) Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. Biol Proced Online 13: 1.
28. Chen G, Kronenberger P, Umelo IA, Teugels E, De Greve J, (2010) Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Anal Biochem 398: 266-268.
29. Chen G, Kronenberger P, Teugels E, Umelo IA, De Greve J, (2012) Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med 10: 28.
30. Chen G, Kronenberger P, Teugels E, Umelo IA, De Greve J, (2013) Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Biochem Biophys Res Commun 431: 623-629.
31. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.